Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share

v3.20.1
Net Loss Per Share
3 Months Ended
Mar. 31, 2020
Net Loss Per Share  
Net Loss Per Share

11. Net Loss Per Share

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the periods. Fully diluted net loss per common share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the periods. Common equivalent shares consist of stock options and warrants that are computed using the treasury stock method.

For the quarters ended March 31, 2020 and 2019, all of the Company’s common stock options, unvested restricted stock units and warrants are anti-dilutive and therefore have been excluded from the diluted calculation.

The following table reconciles net loss to net loss attributable to Heat Biologics, Inc.:

 

 

 

 

 

 

 

 

 

For the Three Months Ended

 

 

March 31,

 

    

2020

    

2019

Net loss

 

$

(6,373,420)

 

$

(5,819,081)

Net loss - Non-controlling interest

 

 

(81,314)

 

 

(103,605)

Net loss attributable to Heat Biologics, Inc.

 

$

(6,292,106)

 

$

(5,715,476)

 

 

 

 

 

 

 

Weighted-average number of common shares used in net loss per share attributable to common stockholders —basic and diluted

 

 

57,282,075

 

 

33,225,164

Net loss per share attributable to Heat Biologics, Inc —basic and diluted

 

$

(0.11)

 

$

(0.17)

 

The following potentially dilutive securities were excluded from the calculation of diluted net loss per share in the three months ended March 31, 2020 and 2019 due to their anti-dilutive effect:

 

 

 

 

 

 

 

 

For the Three Months Ended

 

 

March 31, 

 

    

2020

    

2019

Outstanding stock options

 

5,595,560

 

3,008,754

Restricted stock subject to forfeiture and restricted stock units

 

2,025,215

 

838,679

Outstanding common stock warrants

 

5,779,064

 

9,030,730